Psychedelic drugs have recently returned to the spotlight in medical research. Scientists around the world are studying whether substances once considered dangerous or purely recreational could help treat serious illnesses.
One of the most famous examples is psilocybin, a natural compound found in so‑called “magic mushrooms.” Over the past decade, researchers have discovered that psilocybin may help people with depression, anxiety, addiction, and even some brain diseases.
However, the powerful hallucinations it produces have raised concerns about its safety and practicality as a medical treatment.
Now a new study suggests scientists may be able to keep the medical benefits of these compounds while reducing their mind‑altering effects. Researchers recently reported that they created modified versions of psilocin, the active substance produced when psilocybin is processed in the human body.
Early experiments in mice suggest that these new molecules still affect the brain in useful ways but cause far fewer psychedelic‑like behaviors.
The research was published in the Journal of Medicinal Chemistry, a scientific journal of the American Chemical Society. The study was led by scientists Sara De Martin, Andrea Mattarei, and Paolo Manfredi. Their work focuses on finding ways to make psychedelic‑inspired medicines that may be easier and safer to use in medical settings.
To understand why this research matters, it helps to know how psilocybin works in the brain. Psilocybin itself is not the main active compound. After someone consumes it, the body converts it into another molecule called psilocin.
Psilocin interacts with serotonin receptors in the brain. Serotonin is an important chemical messenger that helps regulate mood, emotions, sleep, and many other brain functions.
Many mental health conditions are linked to problems with serotonin signaling. For example, depression, anxiety disorders, and certain neurodegenerative diseases such as Alzheimer’s disease are often associated with changes in how serotonin works in the brain.
Because psilocybin strongly affects serotonin pathways, scientists believe it may help “reset” certain brain networks that become disrupted in these illnesses.
However, the same brain effects that may provide therapeutic benefits also produce intense hallucinations and altered states of consciousness.
While some clinical trials have carefully supervised psychedelic experiences as part of therapy, the hallucinations can be frightening or uncomfortable for some patients. They also require trained therapists and controlled environments, which limits how widely the treatment can be used.
Because of this challenge, scientists have been searching for ways to separate the helpful biological effects of psychedelics from the strong hallucinogenic experiences they produce. The new study explored this idea by creating modified forms of psilocin that behave slightly differently inside the body.
The research team designed five new chemical versions of psilocin. These compounds were engineered so that they would release psilocin more slowly and steadily in the brain. The idea was that a gradual release might still activate important serotonin receptors but reduce the sudden surge of brain activity believed to trigger hallucinations.
The scientists first tested these new compounds in laboratory experiments. They examined how stable the molecules were in human plasma and in conditions that mimic the digestive system. These early tests helped the researchers identify the most promising candidate, which they named compound 4e.
Compound 4e showed strong stability and released psilocin gradually rather than rapidly. Importantly, it still activated the same serotonin receptors that are thought to produce therapeutic effects.
Next, the researchers tested the compound in mice. The animals were given either compound 4e or standard pharmaceutical‑grade psilocybin by mouth. The scientists then measured how much psilocin appeared in the animals’ blood and brains over a 48‑hour period.
The results showed that compound 4e was able to cross the blood‑brain barrier efficiently. However, instead of producing a quick spike of psilocin in the brain, it generated lower but longer‑lasting levels of the compound.
The researchers also examined the animals’ behavior. In mice, scientists often measure something called the “head twitch response.” This movement is widely used as a reliable indicator of psychedelic‑like activity in rodents.
Mice that received compound 4e showed far fewer head twitches than mice given psilocybin, even though the compound still interacted strongly with serotonin receptors. This suggests the new molecule may activate important brain pathways without producing the same level of psychedelic effects.
According to the researchers, the difference likely comes from how quickly and how strongly psilocin appears in the brain. A slower and more controlled release may allow the brain to respond differently compared with the rapid surge caused by psilocybin.
These findings support a growing idea among scientists: the beneficial brain effects of psychedelics might be separate from the hallucinations themselves. If this is true, it could open the door to a completely new class of medicines inspired by psychedelic compounds but without the intense mind‑altering experiences.
However, the researchers emphasize that this work is still at an early stage. The experiments were performed in laboratory tests and in mice, not in humans. Many additional studies will be needed to understand exactly how these molecules affect the brain and whether they are safe for people.
It is also important to recognize that the current results mainly show biological activity rather than direct therapeutic benefits. Scientists still need to determine whether these compounds can actually treat conditions such as depression, addiction, or neurodegenerative diseases.
Even so, the study represents an exciting step forward in psychedelic research. It shows that scientists may be able to redesign natural psychedelic molecules to make them more suitable for medicine. Instead of producing intense psychedelic experiences, future drugs might gently adjust brain chemistry to improve mood or brain health.
From a broader scientific perspective, this research highlights how modern chemistry and neuroscience can work together to transform controversial substances into potential medicines.
If future studies confirm these findings, the approach could help create safer treatments that combine the powerful brain effects of psychedelics with fewer risks and fewer barriers to medical use.
If you care about depression, please read studies about how dairy foods may influence depression risk, and B vitamins could help prevent depression and anxiety.
For more information about mental health, please see recent studies that ultra-processed foods may make you feel depressed, and extra-virgin olive oil could reduce depression symptoms.
Copyright © 2026 Knowridge Science Report. All rights reserved.
